{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018409","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.004972+00:00","generated_at":"2026-06-05T19:34:49.266712+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M","bullets":["Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.","Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.","Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.","Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.","Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018409","json":"https://secwatch.observer/filing/0000950170-24-018409.json","markdown":"https://secwatch.observer/filing/0000950170-24-018409.md","text":"https://secwatch.observer/filing/0000950170-24-018409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/amlx-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:34:49.266712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cdd4702e1091d230a4be0ecaff7917eb01810d5","claim":"Amylyx Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $108.4 million, net income $4.7 million.","evidence_excerpt":"• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$108.4 million"},{"label":"Net income","value":"$4.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c1b80cf4ac4f490d68041283ab08e389b4ec5a6d","claim":"Amylyx Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $380.8 million, net income $49.3 million.","evidence_excerpt":"• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$380.8 million"},{"label":"Net income","value":"$49.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}